Psychemedics Begin Period Cash Flow vs Free Cash Flow Analysis
PMD Stock | USD 2.72 0.01 0.37% |
Psychemedics financial indicator trend analysis is much more than just breaking down Psychemedics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Psychemedics is a good investment. Please check the relationship between Psychemedics Begin Period Cash Flow and its Free Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.
Begin Period Cash Flow vs Free Cash Flow
Begin Period Cash Flow vs Free Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Psychemedics Begin Period Cash Flow account and Free Cash Flow. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Psychemedics' Begin Period Cash Flow and Free Cash Flow is -0.14. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Psychemedics, assuming nothing else is changed. The correlation between historical values of Psychemedics' Begin Period Cash Flow and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Psychemedics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., Psychemedics' Begin Period Cash Flow and Free Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.14 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Most indicators from Psychemedics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Psychemedics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.The current year's Enterprise Value is expected to grow to about 44.4 M, whereas Selling General Administrative is forecasted to decline to about 6.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 49K | 43K | 49.5K | 47.0K | Depreciation And Amortization | 3.7M | 3.3M | 2.7M | 2.8M |
Psychemedics fundamental ratios Correlations
Click cells to compare fundamentals
Psychemedics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Psychemedics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.5M | 24.0M | 21.6M | 18.7M | 12.3M | 15.1M | |
Total Current Liabilities | 5.8M | 3.9M | 5.8M | 5.7M | 4.7M | 2.7M | |
Total Stockholder Equity | 16.8M | 12.5M | 12.2M | 10.8M | 6.7M | 10.9M | |
Property Plant And Equipment Net | 13.7M | 13.5M | 10.2M | 7.3M | 4.9M | 4.8M | |
Net Debt | (1.3M) | 6.1M | 3.1M | (1.2M) | 334K | 350.7K | |
Retained Earnings | (3.8M) | (8.6M) | (9.6M) | (11.8M) | (16.8M) | (15.9M) | |
Cash | 7.3M | 2.8M | 2.0M | 4.8M | 2.0M | 3.4M | |
Non Current Assets Total | 14.7M | 14.4M | 11.3M | 8.8M | 5.5M | 5.4M | |
Cash And Short Term Investments | 7.3M | 2.8M | 2.0M | 4.8M | 2.0M | 1.9M | |
Net Receivables | 3.8M | 5.9M | 6.8M | 4.1M | 3.7M | 3.6M | |
Common Stock Shares Outstanding | 5.5M | 5.5M | 5.5M | 5.6M | 5.7M | 5.4M | |
Liabilities And Stockholders Equity | 27.5M | 24.0M | 21.6M | 18.7M | 12.3M | 15.1M | |
Non Current Liabilities Total | 4.9M | 7.6M | 3.5M | 2.2M | 945K | 1.8M | |
Other Stockholder Equity | 22.2M | 22.7M | 23.4M | 24.2M | 25.0M | 23.3M | |
Total Liab | 10.7M | 11.5M | 9.3M | 8.0M | 5.7M | 4.2M | |
Total Current Assets | 12.9M | 9.6M | 10.3M | 10.0M | 6.8M | 9.7M | |
Non Currrent Assets Other | (901K) | (1.7M) | 864K | 823K | 632K | 663.6K | |
Other Current Assets | 1.8M | 914K | 1.5M | 1.1M | 1.0M | 1.6M | |
Short Long Term Debt Total | 6.0M | 8.9M | 5.1M | 3.6M | 2.3M | 3.3M | |
Other Current Liab | 3.6M | 922K | 2.0M | 2.1M | 1.0M | 1.5M | |
Short Term Debt | 1.6M | 2.4M | 2.6M | 2.4M | 2.4M | 1.4M | |
Accounts Payable | 617K | 577K | 994K | 448K | 752K | 601.5K | |
Property Plant And Equipment Gross | 13.7M | 13.5M | 10.2M | 7.3M | 28.5M | 29.9M | |
Accumulated Other Comprehensive Income | (238K) | (1.4M) | (1.6M) | (1.6M) | (1.9M) | (2.0M) | |
Other Assets | 943K | 14.4M | 1.0M | 1.5M | 1.7M | 1.2M | |
Property Plant Equipment | 10.9M | 13.5M | 10.2M | 7.3M | 8.3M | 6.2M | |
Net Tangible Assets | 16.8M | 12.5M | 12.2M | 10.8M | 12.4M | 15.1M | |
Long Term Debt | 2.0M | 3.4M | 599K | 305K | 350.8K | 333.2K | |
Retained Earnings Total Equity | (2.1M) | (1.3M) | (3.8M) | (8.6M) | (9.9M) | (10.4M) | |
Capital Surpluse | 31.0M | 31.5M | 32.2M | 32.8M | 37.7M | 33.3M | |
Deferred Long Term Liab | 737K | 740K | 700K | 600K | 540K | 877.6K | |
Other Liab | 1.2M | 955K | 550K | 211K | 189.9K | 180.4K | |
Long Term Debt Total | 2.4M | 1.2M | 2.0M | 3.4M | 3.1M | 2.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Psychemedics is a strong investment it is important to analyze Psychemedics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Psychemedics' future performance. For an informed investment choice regarding Psychemedics Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psychemedics. If investors know Psychemedics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psychemedics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Earnings Share (0.50) | Revenue Per Share 3.586 | Quarterly Revenue Growth (0.15) | Return On Assets (0.16) |
The market value of Psychemedics is measured differently than its book value, which is the value of Psychemedics that is recorded on the company's balance sheet. Investors also form their own opinion of Psychemedics' value that differs from its market value or its book value, called intrinsic value, which is Psychemedics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psychemedics' market value can be influenced by many factors that don't directly affect Psychemedics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psychemedics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Psychemedics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psychemedics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.